Aldo-Keto Reductase Family 1 Member C3
"Aldo-Keto Reductase Family 1 Member C3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Aldo-keto reductase that functions as a bi-directional 17 BETA, 20 ALPHA-HYDROXYSTEROID DEHYDROGENASE. It catalyzes the reduction of PROSTAGLANDIN D2 and PROSTAGLANDIN H2, as well as the oxidation of 9alpha,11beta-PGF2 to prostaglandin D2. It can also interconvert estrogens, ANDROGENS; and PROGESTINS between their active forms and inactive metabolites.
| Descriptor ID |
D000074425
|
| MeSH Number(s) |
D08.811.682.047.150.700.156.875 D08.811.682.047.436.375.140 D08.811.682.047.820.284.937 D08.811.682.047.820.375.500
|
| Concept/Terms |
Aldo-Keto Reductase Family 1 Member C3- Aldo-Keto Reductase Family 1 Member C3
- Aldo Keto Reductase Family 1 Member C3
- 17-beta-Hydroxysteroid Dehydrogenase Type 5
- 17 beta Hydroxysteroid Dehydrogenase Type 5
- AKR1C3 Protein
- Dihydrodiol Dehydrogenase 3
|
Below are MeSH descriptors whose meaning is more general than "Aldo-Keto Reductase Family 1 Member C3".
Below are MeSH descriptors whose meaning is more specific than "Aldo-Keto Reductase Family 1 Member C3".
This graph shows the total number of publications written about "Aldo-Keto Reductase Family 1 Member C3" by people in this website by year, and whether "Aldo-Keto Reductase Family 1 Member C3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aldo-Keto Reductase Family 1 Member C3" by people in Profiles.
-
Transition from androgenic to neurosteroidal action of 5a-androstane-3a, 17ß-diol through the type A ?-aminobutyric acid receptor in prostate cancer progression. J Steroid Biochem Mol Biol. 2018 04; 178:89-98.
-
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung. Int J Clin Exp Pathol. 2013; 6(11):2419-29.
-
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. Int J Clin Exp Pathol. 2012; 5(4):278-89.
-
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol. 2010 Jul 05; 3(6):608-17.
-
Differential expression of type 2 3a/type 5 17ß-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system. Int J Clin Exp Pathol. 2010 Mar 25; 3(8):743-54.
-
Developmental evaluation of aldo-keto reductase 1C3 expression in the cryptorchid testis. Urology. 2010 Jul; 76(1):67-72.
-
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Exp Pathol. 2009 Nov 15; 3(2):147-55.
-
Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system. J Histochem Cytochem. 2008 Sep; 56(9):853-61.
-
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol. 2008 Jul 16; 289(1-2):60-6.
-
Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer. 2006 Mar; 13(1):169-80.